A phase 2 study to assess the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy Meeting Abstract
| Authors: | Mato, A. R.; Schuster, S. J.; Lamanna, N.; Pagel, J. M.; Flinn, I. W.; Barrientos, J.; Reeves, J. A.; Cheson, B. D.; Barr, P. M.; Kambhampati, S.; Lansigan, F.; Pu, J. J.; Skarbnik, A.; Fonseca, G.; Dorsey, C.; LaRatta, N. M.; Weissbrot, H.; Svoboda, J.; Luning Prak, E. T.; Tsao, P.; Sitlinger, A.; Paskalis, D.; Sportelli, P.; Miskin, H. P.; Weiss, M. S.; Brander, D. M. |
| Abstract Title: | A phase 2 study to assess the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy |
| Meeting Title: | 15th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 37 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2019 Jun 18-22 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2019-06-01 |
| Start Page: | 88 |
| End Page: | 89 |
| Language: | English |
| ACCESSION: | 136932774 |
| DOI: | 10.1002/hon.56_2629 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| PUBMED: | 31187525 |
| DOI/URL: | |
| Notes: | Meeting abstract: 050 -- Accession Number: 136932774 -- Entry Date: In Process -- Revision Date: 20190617 -- Publication Type: Article -- Supplement Title: Jun2019 Supplement S1 -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
Altmetric
Citation Impact
BMJ Impact Analytics
